Singular Research Initiates Coverage Of Nymox With "Buy" Rating
HASBROUCK HEIGHTS, N.J., July 21, 2010 (GLOBE NEWSWIRE) -- Singular Research has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with a "Buy" rating and a 12 month target price of $11.00. The report was written by Gregory P. Garner, CFA, an equity research analyst for Singular Research. According to the report, "Nymox Pharmaceutical is a pharmaceutical development company with a very promising compound for enlarged prostate that is in Phase 3 clinical trials…several anticipated events in the coming 12 to 18 months will lead to greater investor awareness of the product and push valuations upwards, in our opinion."
About Nymox: NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials, please go to www.clinicaltrials.gov or contact Nymox at firstname.lastname@example.org. BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669. Nymox made no payments to Singular Research for the research report.
About Singular Research: Singular Research aims to be the most trusted supplier of independent research on small-cap companies. Singular analysts research high-quality companies that are typically not covered by any other firms. We provide Honest Advice: Our Independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees. For more information, visit: www.singularresearch.com, or call 818-222-6915.This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Nymox Pharmaceutical Corporation Roy Wolvin 1-800-93NYMOX www.nymox.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV